A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.
Jayachandra Reddy and Rishit Thakkar discuss the challenges facing early entrants in the Non-alcoholic Steatohepatitis market.